NO20034149L - Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel - Google Patents
Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddelInfo
- Publication number
- NO20034149L NO20034149L NO20034149A NO20034149A NO20034149L NO 20034149 L NO20034149 L NO 20034149L NO 20034149 A NO20034149 A NO 20034149A NO 20034149 A NO20034149 A NO 20034149A NO 20034149 L NO20034149 L NO 20034149L
- Authority
- NO
- Norway
- Prior art keywords
- triazaspiro
- active ingredient
- medicines containing
- undecane derivatives
- undecane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001079611 | 2001-03-19 | ||
PCT/JP2002/002553 WO2002074769A1 (fr) | 2001-03-19 | 2002-03-18 | Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034149D0 NO20034149D0 (no) | 2003-09-17 |
NO20034149L true NO20034149L (no) | 2003-11-19 |
Family
ID=18936022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034149A NO20034149L (no) | 2001-03-19 | 2003-09-17 | Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel |
Country Status (17)
Country | Link |
---|---|
US (1) | US7285552B2 (fr) |
EP (1) | EP1378509A4 (fr) |
JP (1) | JPWO2002074769A1 (fr) |
KR (1) | KR20030093248A (fr) |
CN (1) | CN1533390A (fr) |
BR (1) | BR0208229A (fr) |
CA (1) | CA2441162A1 (fr) |
CZ (1) | CZ20032532A3 (fr) |
HU (1) | HUP0400241A2 (fr) |
IL (1) | IL157940A0 (fr) |
MX (1) | MXPA03008528A (fr) |
NO (1) | NO20034149L (fr) |
NZ (1) | NZ528270A (fr) |
PL (1) | PL364469A1 (fr) |
RU (1) | RU2003128075A (fr) |
WO (1) | WO2002074769A1 (fr) |
ZA (1) | ZA200307318B (fr) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60212110T2 (de) | 2001-03-19 | 2006-11-09 | Ono Pharmaceutical Co. Ltd. | Triazaspiro (5.5) undecanderivate und arzneimittel, die diese derivate als wirkstoff enthalten |
KR20050057408A (ko) * | 2002-09-18 | 2005-06-16 | 오노 야꾸힝 고교 가부시키가이샤 | 트리아자스피로[5.5]운데칸 유도체 및 이를 유효 성분으로하는 약제 |
AU2003271057A1 (en) * | 2002-09-18 | 2004-04-08 | Ono Pharmaceutical Co., Ltd. | Novel crystals of triazaspiro(5.5)undecane derivative |
EP1570860A4 (fr) * | 2002-12-13 | 2009-06-03 | Ono Pharmaceutical Co | Antagoniste et agoniste se liant a un site de liaison forte du recepteur de la chimiokine |
EP1621540A4 (fr) * | 2003-04-21 | 2008-07-23 | Ono Pharmaceutical Co | Composes heterocycliques contenant de l'azote et utilisation de celui-ci |
JP5135795B2 (ja) * | 2004-08-27 | 2013-02-06 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
EP1819333A1 (fr) * | 2004-12-01 | 2007-08-22 | Boehringer Ingelheim International Gmbh | Methode de traitement de l'infection a vih par co-administration de tipranavir et de gw873140 |
WO2010009196A1 (fr) * | 2008-07-15 | 2010-01-21 | Temple University Of The Commonwealth System Of Higher Education | Synthèse d’oligomères de bis-peptides comportant au moins une dicétopipérazine n-substituée en tant que groupe fonctionnel structurel |
BRPI0917013A2 (pt) | 2008-08-11 | 2016-02-16 | Glaxosmithkline Llc | métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
JP2011530562A (ja) | 2008-08-11 | 2011-12-22 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
EP2534148A1 (fr) | 2010-02-10 | 2012-12-19 | GlaxoSmithKline LLC | Dérivés de purine et leurs utilisations pharmaceutiques |
ES2525826T3 (es) | 2010-02-10 | 2014-12-30 | Glaxosmithkline Llc | Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona |
EP2624696B1 (fr) | 2010-10-06 | 2016-12-21 | Glaxosmithkline LLC | Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase |
US8609653B2 (en) | 2011-07-15 | 2013-12-17 | Glaxosmithkline Llc | Azaindole compounds and methods for treating HIV |
EP2757887B1 (fr) | 2011-09-22 | 2017-04-26 | VIIV Healthcare UK Limited | Composés pyrrolopyridinones et méthodes de traitement du vih |
JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
WO2014009794A1 (fr) | 2012-07-12 | 2014-01-16 | Viiv Healthcare Uk Limited | Composés et procédés de traitement du vih |
KR20160124157A (ko) | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
WO2016075661A1 (fr) | 2014-11-13 | 2016-05-19 | Glaxosmithkline Biologicals Sa | Dérivés d'adénine utiles pour traiter des maladies allergiques ou d'autres pathologies inflammatoires |
UY36758A (es) | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
WO2017002078A1 (fr) | 2015-07-02 | 2017-01-05 | Glaxosmithkline Intellectual Property Development Limited | Inhibiteurs d'indoléamine 2,3-dioxygénase |
JP2018521107A (ja) | 2015-07-28 | 2018-08-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Hiv感染を予防または治療するためのベツイン誘導体 |
RU2018105343A (ru) | 2015-07-28 | 2019-08-28 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Производные бетулина для предупреждения или лечения ВИЧ-инфекций |
JP2018528231A (ja) | 2015-09-24 | 2018-09-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Hiv成熟阻害活性を有する化合物 |
EP3322713B1 (fr) | 2015-12-03 | 2021-01-20 | GlaxoSmithKline Intellectual Property Development Limited | Dinucléotides cycliques de purine à titre de modulateurs du sting |
WO2017130156A1 (fr) | 2016-01-27 | 2017-08-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Analogues d'igénol, compositions pharmaceutiques et méthodes d'utilisation de ces derniers |
US10975287B2 (en) | 2016-04-07 | 2021-04-13 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
EP4032885A1 (fr) | 2016-04-07 | 2022-07-27 | GlaxoSmithKline Intellectual Property Development Limited | Amides hétérocycliques utiles en tant que modulateurs de protéine |
WO2017191545A1 (fr) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Activateur d'inhibiteurs de l'homologue 2 de zeste |
WO2018002902A1 (fr) | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Conjugués anticorps-médicament et procédés thérapeutiques utilisant ceux-ci |
WO2018083087A2 (fr) | 2016-11-02 | 2018-05-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Protéines de liaison |
UY37710A (es) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
CA3077337A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des genes (sting) de l'interferon |
WO2019069269A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih |
US11274102B2 (en) | 2017-10-30 | 2022-03-15 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
US20200407393A1 (en) | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
ES2962736T3 (es) | 2018-04-11 | 2024-05-24 | Viiv Healthcare Uk No 5 Ltd | Compuestos de 4-oxo-3,4-dihidroquinazolina como inhibidores de la replicación del virus de la inmunodeficiencia humana |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
JP2021534112A (ja) | 2018-08-09 | 2021-12-09 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Hiv療法に有用な化合物 |
JP2021536444A (ja) | 2018-08-30 | 2021-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Hiv療法に有用な化合物 |
IL283487B2 (en) | 2018-11-30 | 2024-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds useful in curing HIV |
PE20212089A1 (es) | 2019-03-06 | 2021-11-04 | Glaxosmithkline Ip No 2 Ltd | Compuestos utiles en la terapia del vih |
WO2020232375A1 (fr) | 2019-05-16 | 2020-11-19 | Silicon Swat, Inc. | Dérivés d'acide oxoacridinyle acétique et procédés d'utilisation |
EP3969452A1 (fr) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Dérivés d'acide acétique benzo[b][1,8]naphtyridine et leur procédés d'utilisation |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
EP4010349A1 (fr) | 2019-08-08 | 2022-06-15 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Dérivés de 4'-éthynyle -2'-désoxyadénosine et leur utilisation en thérapie contre le vih |
EP4021916A1 (fr) | 2019-08-28 | 2022-07-06 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Dérivés de 4'-éthynyle -2'-désoxyadénosine et leur utilisation dans la thérapie contre le vih |
EP4298105A1 (fr) | 2021-02-23 | 2024-01-03 | VIIV Healthcare Company | Composés utiles dans le traitement du vih |
TW202412757A (zh) | 2022-05-27 | 2024-04-01 | 美商 Viiv 醫療保健公司 | 用於hiv治療之化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS231227B1 (en) * | 1982-10-01 | 1984-10-15 | Evzen Kasafirek | 2,5-pierazindion derivatives |
WO1993013101A1 (fr) * | 1991-12-27 | 1993-07-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro |
AU713235B2 (en) | 1995-09-29 | 1999-11-25 | Cor Therapeutics, Inc. | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
US6288083B1 (en) * | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US7119091B2 (en) | 1999-12-03 | 2006-10-10 | Ono Pharmaceutical Co., Ltd. | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient |
FR2804882B1 (fr) | 2000-02-11 | 2002-05-10 | Air Liquide | Procede de compression d'air atmospherique |
DE60212110T2 (de) | 2001-03-19 | 2006-11-09 | Ono Pharmaceutical Co. Ltd. | Triazaspiro (5.5) undecanderivate und arzneimittel, die diese derivate als wirkstoff enthalten |
-
2002
- 2002-03-18 BR BR0208229-2A patent/BR0208229A/pt not_active IP Right Cessation
- 2002-03-18 WO PCT/JP2002/002553 patent/WO2002074769A1/fr active IP Right Grant
- 2002-03-18 MX MXPA03008528A patent/MXPA03008528A/es unknown
- 2002-03-18 CN CNA028098331A patent/CN1533390A/zh active Pending
- 2002-03-18 RU RU2003128075/15A patent/RU2003128075A/ru not_active Application Discontinuation
- 2002-03-18 US US10/472,626 patent/US7285552B2/en not_active Expired - Fee Related
- 2002-03-18 EP EP02705300A patent/EP1378509A4/fr not_active Withdrawn
- 2002-03-18 PL PL02364469A patent/PL364469A1/xx not_active Application Discontinuation
- 2002-03-18 JP JP2002573778A patent/JPWO2002074769A1/ja not_active Ceased
- 2002-03-18 CA CA002441162A patent/CA2441162A1/fr not_active Abandoned
- 2002-03-18 KR KR10-2003-7012131A patent/KR20030093248A/ko not_active Application Discontinuation
- 2002-03-18 IL IL15794002A patent/IL157940A0/xx unknown
- 2002-03-18 HU HU0400241A patent/HUP0400241A2/hu unknown
- 2002-03-18 CZ CZ20032532A patent/CZ20032532A3/cs unknown
- 2002-03-18 NZ NZ528270A patent/NZ528270A/en not_active Application Discontinuation
-
2003
- 2003-09-17 NO NO20034149A patent/NO20034149L/no unknown
- 2003-09-18 ZA ZA200307318A patent/ZA200307318B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20034149D0 (no) | 2003-09-17 |
KR20030093248A (ko) | 2003-12-06 |
RU2003128075A (ru) | 2005-04-10 |
JPWO2002074769A1 (ja) | 2004-07-08 |
NZ528270A (en) | 2005-10-28 |
CZ20032532A3 (en) | 2004-03-17 |
US7285552B2 (en) | 2007-10-23 |
EP1378509A4 (fr) | 2009-03-25 |
CN1533390A (zh) | 2004-09-29 |
ZA200307318B (en) | 2004-07-29 |
IL157940A0 (en) | 2004-03-28 |
PL364469A1 (en) | 2004-12-13 |
MXPA03008528A (es) | 2004-06-30 |
BR0208229A (pt) | 2004-03-09 |
WO2002074769A1 (fr) | 2002-09-26 |
HUP0400241A2 (hu) | 2004-06-28 |
EP1378509A1 (fr) | 2004-01-07 |
US20040106619A1 (en) | 2004-06-03 |
CA2441162A1 (fr) | 2002-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20034149D0 (no) | Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel | |
PL376154A1 (en) | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | |
AU2002238947A1 (en) | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | |
ITTO20010005A1 (it) | Formulazione farmaceutica. | |
NO20041567L (no) | 1,8-nafthyridinderivater som antidiabetiske midler | |
MXPA03006775A (es) | Formulacion farmaceutica. | |
NO20043702L (no) | 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel | |
NO20015477L (no) | 4,5,6,7-tetrahydroindazolderivater som antitumormidler | |
NO20002217D0 (no) | Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler | |
NO20042807L (no) | Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser | |
MA26385A1 (fr) | Derives de 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate | |
NO20013671L (no) | Substituerte bisycliske derivater nyttige som anticancer midler | |
MXPA03007641A (es) | Formulacion farmaceutica. | |
DK1401841T3 (da) | Substituerede 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivater som lægemidler mod smerte | |
DK1498411T3 (da) | Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel | |
PL360294A1 (en) | Propane-1,3-dione derivatives | |
NO20042739L (no) | Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan | |
HUP0400155A3 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
AU2002238855A1 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
IS6980A (is) | 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum | |
DK1118610T3 (da) | Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne | |
HUP0600084A2 (en) | Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient | |
IS6989A (is) | 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum | |
NO20041878L (no) | Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel. | |
NO20030474D0 (no) | Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel |